- US-listed companies
- Moleculin Biotech, Inc.
Moleculin Biotech, Inc.MBRX
Market cap
$73.33M
P/E ratio
| Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
| Revenue | - | - | - | - | - | - | - |
| Research and development | 1 | 5 | 10 | 11 | 13 | 14 | 19 |
| General and administrative | 2 | 4 | 5 | 6 | 7 | 8 | 12 |
| Depreciation and amortization | 6,162 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 4 | 9 | 15 | 18 | 20 | 23 | 31 |
| Loss from operations | -3,883,147 | -9 | -15 | -18 | -20 | -23 | -31 |
| Gain from change in fair value of warrant liability | - | 3 | -3 | -4 | -2 | -7 | -1 |
| Other income, net | - | - | -0 | 0 | 0 | 0 | 0 |
| Interest income, net | - | - | 0 | 0 | 0 | 0 | 0 |
| Net loss | -3,926,361 | -10 | -12 | -13 | -17 | -16 | -29 |
| Net loss per common share - basic and diluted (in dollars per share) | - | - | - | - | - | - | -1.01 |
| Net loss | -3,926,361 | -10 | -12 | -13 | -17 | -16 | -29 |
| Foreign currency translation | - | - | 0 | -0 | 0 | -0 | -0 |
| Comprehensive loss | - | - | -12 | -13 | -17 | -16 | -29 |